Radius Health

Radius Health PP&E per Employee

Delisted

The PP&E per Employee of Radius Health (RDUS) as of Nov 3, 2026 is 261,219.86 USD. In the previous year, PP&E per Employee was 230,453.34 USD — a change of 13.35% (higher).

PP&E per Employee

261,219.86USD

YoY

13.35%

Last updated:

PP&E per Employee of Radius Health is 2022 261,219.86 USD. PP&E per Employee of Radius Health was 2021 230,453.34 USD. It decreases by 13.35% higher compared to the previous year.

The Radius Health PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
141,997.34 USD
Jan 1, 2016
130,461.64 USD
Jan 1, 2017
129,733.98 USD
Jan 1, 2018
138,064.10 USD
Jan 1, 2019
151,577.55 USD
Jan 1, 2020
161,741.61 USD
Jan 1, 2021
230,453.34 USD
Jan 1, 2022
261,219.86 USD
The Radius Health PP&E per Employee history
YEARPP&E per EmployeeYoY
261,219.86USD+13.35%
230,453.34USD+42.48%
161,741.61USD+6.71%
151,577.55USD+9.79%
138,064.10USD+6.42%
129,733.98USD-0.56%
130,461.64USD-8.12%
141,997.34USD-18.32%
173,840.25USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Radius Health Stock analysis

What does Radius Health do? Radius Health Inc. is an American pharmaceutical company specializing in the research, development, and marketing of products in the areas of osteoporosis, cancer therapy, and endocrinology. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. The history of Radius Health Inc. began with the discovery of a new compound called Abaloparatide, which was intended for use in the treatment of osteoporosis. The company initiated a Phase III clinical trial to evaluate the efficacy and tolerability of the medication. In 2016, Abaloparatide was approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Since then, Radius Health Inc. has evolved into a leading company specializing in improving women's health. The company has expanded its activities to include oncology and endocrinology and relies on innovative technologies and research to provide better treatment options and medications for patients. The business model of Radius Health Inc. is based on the development and marketing of cost-effective and effective products for the treatment of diseases. The company conducts extensive clinical research and strives to develop new drugs and therapies to improve the lives of women. Radius Health Inc. employs an open and agile corporate culture that promotes innovation and prioritizes the needs of patients. The products offered by Radius Health Inc. include a wide range of medications used in the treatment of osteoporosis, breast cancer, and other diseases. Abaloparatide, the company's flagship product, is a recombinant peptide agonist that stimulates bone formation and reduces the risk of fractures in postmenopausal women. Other products include Elacestrant, an investigative drug for the treatment of breast cancer, and RAD1901, a selective estrogen receptor modulator used in the treatment of hormone-dependent cancers. The company is also active in the field of digital health. Radius Health Inc. has developed an augmented reality app that assists doctors and patients in visualizing bone fractures and other conditions. The app is currently being tested in clinical trials and is expected to be widely used in the future. Overall, Radius Health Inc. is known for its innovative research activities and efforts to improve women's health. The company has an experienced and dedicated team of researchers, scientists, and executives working together to create better treatment options for patients. With a strong pipeline of products and a vision for the future of healthcare, Radius Health Inc. is on track to become a leading provider of medical products and services. Radius Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Radius Health stock

PP&E per Employee of Radius Health is 261,219.86 USD in 2022.

PP&E per Employee of Radius Health changed from 230,453.34 USD to 261,219.86 USD, representing a 13.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Radius Health since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Radius Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Radius Health

All Key Metrics — Radius Health